Aeglea Bio Therapeutics (NASDAQ:AGLE) Shares Gap Down to $9.21

Share on StockTwits

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) gapped down before the market opened on Monday . The stock had previously closed at $8.84, but opened at $9.21. Aeglea Bio Therapeutics shares last traded at $9.71, with a volume of 6,759 shares.

AGLE has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub upgraded shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 17th. HC Wainwright decreased their target price on shares of Aeglea Bio Therapeutics from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Needham & Company LLC initiated coverage on shares of Aeglea Bio Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Piper Sandler initiated coverage on shares of Aeglea Bio Therapeutics in a research note on Monday, May 4th. They set an “overweight” rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Aeglea Bio Therapeutics currently has an average rating of “Buy” and an average target price of $12.31.

The stock has a market cap of $408.47 million, a P/E ratio of -3.81 and a beta of 2.08. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.17 and a quick ratio of 3.17. The firm’s 50-day moving average price is $8.78 and its 200-day moving average price is $7.26.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.08. Sell-side analysts expect that Aeglea Bio Therapeutics Inc will post -1.71 earnings per share for the current year.

In related news, CEO Anthony G. Quinn acquired 165,000 shares of Aeglea Bio Therapeutics stock in a transaction dated Thursday, April 30th. The shares were purchased at an average price of $4.75 per share, for a total transaction of $783,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 13.70% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in Aeglea Bio Therapeutics in the first quarter worth $49,000. Bank of New York Mellon Corp increased its position in Aeglea Bio Therapeutics by 5.3% in the first quarter. Bank of New York Mellon Corp now owns 95,106 shares of the biotechnology company’s stock worth $443,000 after purchasing an additional 4,763 shares during the last quarter. Marshall Wace LLP increased its position in Aeglea Bio Therapeutics by 4.1% in the fourth quarter. Marshall Wace LLP now owns 833,407 shares of the biotechnology company’s stock worth $6,367,000 after purchasing an additional 32,800 shares during the last quarter. Citigroup Inc. increased its position in Aeglea Bio Therapeutics by 191.2% in the fourth quarter. Citigroup Inc. now owns 7,610 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 4,997 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Aeglea Bio Therapeutics by 1.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 442,050 shares of the biotechnology company’s stock worth $3,377,000 after purchasing an additional 7,051 shares during the last quarter. Institutional investors own 46.09% of the company’s stock.

Aeglea Bio Therapeutics Company Profile (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Recommended Story: Oversold

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Squarepoint Ops LLC Buys New Position in Rimini Street Inc
Squarepoint Ops LLC Buys New Position in Rimini Street Inc
Nuveen Asset Management LLC Lowers Position in Aldeyra Therapeutics, Inc
Nuveen Asset Management LLC Lowers Position in Aldeyra Therapeutics, Inc
Alliancebernstein L.P. Buys 9,900 Shares of AXT Inc
Alliancebernstein L.P. Buys 9,900 Shares of AXT Inc
Jane Street Group LLC Buys New Shares in Kandi Technologies Group Inc
Jane Street Group LLC Buys New Shares in Kandi Technologies Group Inc
HighTower Advisors LLC Sells 169,893 Shares of Prospect Capital Co.
HighTower Advisors LLC Sells 169,893 Shares of Prospect Capital Co.
689,153 Shares in Two Harbors Investment Corp  Bought by APG Asset Management N.V.
689,153 Shares in Two Harbors Investment Corp Bought by APG Asset Management N.V.


© 2006-2020 Ticker Report